rs771877780
Positions:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 0P and 2B. BP4BS2_Supporting
The NM_004006.3(DMD):c.7555G>A(p.Asp2519Asn) variant causes a missense change. The variant allele was found at a frequency of 0.0000058 in 1,207,821 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 5 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.000018 ( 0 hom., 2 hem., cov: 23)
Exomes 𝑓: 0.0000046 ( 0 hom. 3 hem. )
Consequence
DMD
NM_004006.3 missense
NM_004006.3 missense
Scores
2
6
7
Clinical Significance
Conservation
PhyloP100: 6.67
Genes affected
DMD (HGNC:2928): (dystrophin) This gene spans a genomic range of greater than 2 Mb and encodes a large protein containing an N-terminal actin-binding domain and multiple spectrin repeats. The encoded protein forms a component of the dystrophin-glycoprotein complex (DGC), which bridges the inner cytoskeleton and the extracellular matrix. Deletions, duplications, and point mutations at this gene locus may cause Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), or cardiomyopathy. Alternative promoter usage and alternative splicing result in numerous distinct transcript variants and protein isoforms for this gene. [provided by RefSeq, Dec 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
BP4
?
Computational evidence support a benign effect (MetaRNN=0.27373123).
BS2
?
High Hemizygotes in GnomAd4 at 2 XL geneVariant has number of hemizygotes lower than other variant known as pathogenic in the gene, so the strength is limited to Supporting.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
DMD | NM_004006.3 | c.7555G>A | p.Asp2519Asn | missense_variant | 52/79 | ENST00000357033.9 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
DMD | ENST00000357033.9 | c.7555G>A | p.Asp2519Asn | missense_variant | 52/79 | 1 | NM_004006.3 | P4 |
Frequencies
GnomAD3 genomes ? AF: 0.0000179 AC: 2AN: 111885Hom.: 0 Cov.: 23 AF XY: 0.0000587 AC XY: 2AN XY: 34065
GnomAD3 genomes
?
AF:
AC:
2
AN:
111885
Hom.:
Cov.:
23
AF XY:
AC XY:
2
AN XY:
34065
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000272 AC: 5AN: 183507Hom.: 0 AF XY: 0.0000442 AC XY: 3AN XY: 67943
GnomAD3 exomes
AF:
AC:
5
AN:
183507
Hom.:
AF XY:
AC XY:
3
AN XY:
67943
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000456 AC: 5AN: 1095936Hom.: 0 Cov.: 29 AF XY: 0.00000830 AC XY: 3AN XY: 361320
GnomAD4 exome
AF:
AC:
5
AN:
1095936
Hom.:
Cov.:
29
AF XY:
AC XY:
3
AN XY:
361320
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? AF: 0.0000179 AC: 2AN: 111885Hom.: 0 Cov.: 23 AF XY: 0.0000587 AC XY: 2AN XY: 34065
GnomAD4 genome
?
AF:
AC:
2
AN:
111885
Hom.:
Cov.:
23
AF XY:
AC XY:
2
AN XY:
34065
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
?
AF:
AC:
6
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:3Uncertain:3Benign:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Pathogenic:2Uncertain:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 04, 2015 | The D2519N missense variant has been reported previously as de novo in a male with elevated CK level, calf hypertrophy, and a clinical diagnosis of Duchenne muscular dystrophy (Wang et al., 2014). It was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The D2519N variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved across species. Therefore, D2519N is interpreted as a pathogenic variant. - |
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | May 04, 2022 | The DMD c.7555G>A; p.Asp2519Asn variant (rs771877780) is reported in the literature as occurring de novo in a male diagnosed with muscular dystrophy and in a female with an increased CK undergoing carrier screening (Han 2020, Wang 2014). This variant is reported in the ClinVar database with conflicting classifications (Variation ID: 427170). This variant is found in the East Asian population with an allele frequency of 0.04% (6/14,879 alleles, including 4 hemizygotes) in the Genome Aggregation Database. The aspartic acid at codon 2519 is highly conserved, but computational analyses are uncertain whether this variant is neutral or deleterious (REVEL: 0.254). Although the number of hemizygotes in the Genome Aggregation Database indicates this variant may be a rare benign variant, due to conflicting information, the clinical significance of the p.Asp2519Asn variant is uncertain at this time. References: Han S et al. Population-Wide Duchenne Muscular Dystrophy Carrier Detection by CK and Molecular Testing. Biomed Res Int. 2020 Sep 27;2020:8396429. PMID: 33029525. Wang Y et al. Whole dystrophin gene analysis by next-generation sequencing: a comprehensive genetic diagnosis of Duchenne and Becker muscular dystrophy. Mol Genet Genomics. 2014 Oct;289(5):1013-21. PMID: 24770780. - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jun 01, 2017 | - - |
Duchenne muscular dystrophy Pathogenic:1Benign:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Department of Obstetrics, Zhejiang Provincial People's Hospital, Zhejiang Provincial People's Hospital | Aug 16, 2020 | The D2519N missense variant was not observed in 1000 Genome database, ESP 6500 and genomAD. It was a presumed de novo variant in a female with elevated CK and harboring non-DMD family history. This substitution occurs at a position that is conserved across species (SIFT and PolyPhen predicted it deleterious and probably damaging). Therefore, D2519N is interpreted as a likely pathogenic variant. - |
Benign, criteria provided, single submitter | clinical testing | Invitae | Jan 21, 2024 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 19, 2023 | Variant summary: DMD c.7555G>A (p.Asp2519Asn) results in a conservative amino acid change located in the central rod domain of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.9e-05 in 205897 control chromosomes, predominantly at a frequency of 0.0004 within the East Asian subpopulation in the gnomAD database, including 4 hemizygotes. The available data on variant occurrences in the general population suggest the variant could be a benign polymorphism found predominantly in individuals of East Asian ancestry, but are ultimately insufficient to allow any conclusion about variant significance. c.7555G>A has been reported in the literature as de novo in a male child affected with Duchenne Muscular Dystrophy (DMD) (Wang_2013) as well as in a female carrier with slightly elevated creatine kinase levels but no family history of DMD (Han_2020). These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 33029525, 24770780). Six submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 with conflicting assessments. Three submitters classified the variant as pathogenic/likely pathogenic, two classified it as uncertain significance, and one submitter classified it as benign. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 25, 2022 | The p.D2519N variant (also known as c.7555G>A), located in coding exon 52 of the DMD gene, results from a G to A substitution at nucleotide position 7555. The aspartic acid at codon 2519 is replaced by asparagine, an amino acid with highly similar properties. This variant was described as de novo in one male reported to have symptoms of Duchenne muscular dystrophy (DMD), although clinical details were limited (Wang Y et al. Mol Genet Genomics, 2014 Oct;289:1013-21). This variant was also detected in a female with elevated creatine kinase (CK) levels who had no skeletal muscular or cardiac findings, and known family history of DMD (Han S et al. Biomed Res Int, 2020 Sep;2020:8396429). Based on data from gnomAD, the A allele has an overall frequency of 0.0029%( 6/205497) total alleles studied, with 4 hemizygotes observed. The highest observed frequency was 0.0403% (6/14879) of East Asian alleles. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Pathogenic
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
D;.;.;.;D;.;D;D;.
M_CAP
Uncertain
D
MetaRNN
Benign
T;T;T;T;T;T;T;T;T
MetaSVM
Benign
T
MutationTaster
Benign
D;D;D;D;D;D;D
PrimateAI
Uncertain
T
PROVEAN
Uncertain
D;D;D;D;.;D;.;D;D
REVEL
Benign
Sift
Uncertain
D;D;D;D;.;D;.;D;D
Sift4G
Uncertain
D;D;D;D;D;D;D;D;D
Polyphen
1.0, 1.0, 0.99
.;D;D;D;.;D;.;.;D
Vest4
0.57, 0.52, 0.52, 0.69, 0.61, 0.53, 0.80, 0.42
MutPred
0.46
.;.;.;.;.;.;.;Loss of ubiquitination at K2514 (P = 0.0705);.;
MVP
MPC
0.070
ClinPred
D
GERP RS
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at